Clinical trial
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50…
NCT00441441 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00441441 |
|---|---|
| Title | A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma |
| Official title | A Randomized, Double-blind, Parallel Group Study Evaluating the Safety of Fluticasone Propionate/Salmeterol 100/50mcg HFA (2 Inhalations of 50/25mcg) Twice Daily Compared With Fluticasone Propionate 100mcg HFA (2 Inhalations of 50mcg) Twice Daily in Subjects 4-11 Years of Age With Persistent Asthma |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | fluticasone propionate, fluticasone propionate/salmeterol |
| Enrollment | 351 |
| Start date | Feb 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Mar 1, 2007 |
| Last update posted | Dec 16, 2016 |
| Countries | Australia, Canada, Chile, Costa Rica, Germany, Latvia, Lithuania, Mexico, Peru, Poland, Russia, Spain and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: